Pharmacoeconomics of systemic therapies for lung cancer.

Louise Bordeleau
{"title":"Pharmacoeconomics of systemic therapies for lung cancer.","authors":"Louise Bordeleau","doi":"10.2165/00151829-200605020-00006","DOIUrl":null,"url":null,"abstract":"<p><p>The purpose of this article is to review the economics of systemic therapies for the treatment of lung cancer. Lung cancer treatment is moderately expensive. The overall cost to society is significant given its high incidence. Most analyses in patients with small cell lung cancer focus on supportive care measures. The economics of chemotherapy in patients with advanced small cell lung cancer, as assessed in one study, shows alternating chemotherapy to be cost effective. Numerous economic analyses of chemotherapy in patients with non-small cell lung cancer (NSCLC) have been completed using varying methodologies in a number of countries. In patients with advanced NSCLC, third generation chemotherapy in the first-line setting can be administered within reasonable incremental cost effectiveness. Single-agent docetaxel chemotherapy in the second-line setting has also been shown to fall within a reasonable cost-effective range. Based on this review, systemic therapies for lung cancer are, for the most part, cost effective. Information on the cost-utility of systemic therapies is more limited. In a population of cancer patients with poor prognosis, the inclusion of quality indicators in the calculation of costs (i.e. cost-utility analyses) will be of great importance to refine our understanding of costs and benefits using a more global approach. Future economic analyses of adjuvant chemotherapy and novel targeted therapies will be of great interest.</p>","PeriodicalId":87162,"journal":{"name":"Treatments in respiratory medicine","volume":"5 2","pages":"129-41"},"PeriodicalIF":0.0000,"publicationDate":"2006-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2165/00151829-200605020-00006","citationCount":"13","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Treatments in respiratory medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2165/00151829-200605020-00006","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 13

Abstract

The purpose of this article is to review the economics of systemic therapies for the treatment of lung cancer. Lung cancer treatment is moderately expensive. The overall cost to society is significant given its high incidence. Most analyses in patients with small cell lung cancer focus on supportive care measures. The economics of chemotherapy in patients with advanced small cell lung cancer, as assessed in one study, shows alternating chemotherapy to be cost effective. Numerous economic analyses of chemotherapy in patients with non-small cell lung cancer (NSCLC) have been completed using varying methodologies in a number of countries. In patients with advanced NSCLC, third generation chemotherapy in the first-line setting can be administered within reasonable incremental cost effectiveness. Single-agent docetaxel chemotherapy in the second-line setting has also been shown to fall within a reasonable cost-effective range. Based on this review, systemic therapies for lung cancer are, for the most part, cost effective. Information on the cost-utility of systemic therapies is more limited. In a population of cancer patients with poor prognosis, the inclusion of quality indicators in the calculation of costs (i.e. cost-utility analyses) will be of great importance to refine our understanding of costs and benefits using a more global approach. Future economic analyses of adjuvant chemotherapy and novel targeted therapies will be of great interest.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
肺癌全身治疗的药物经济学。
本文的目的是回顾系统性治疗肺癌的经济学。肺癌治疗费用适中。鉴于其高发病率,社会的总成本是巨大的。大多数对小细胞肺癌患者的分析侧重于支持性护理措施。一项研究评估了晚期小细胞肺癌患者化疗的经济性,表明交替化疗具有成本效益。许多国家已经完成了对非小细胞肺癌(NSCLC)患者化疗的大量经济分析,使用了不同的方法。在晚期非小细胞肺癌患者中,在合理的成本效益增量范围内,第一线的第三代化疗可以给予。单药多西他赛化疗在二线也被证明在合理的成本效益范围内。基于这一综述,在大多数情况下,肺癌的全身治疗是具有成本效益的。关于全身性治疗的成本-效用的信息更为有限。在预后不良的癌症患者群体中,在成本计算中纳入质量指标(即成本效用分析)对于使用更全面的方法改进我们对成本和收益的理解将具有重要意义。未来对辅助化疗和新型靶向治疗的经济分析将引起人们的极大兴趣。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Idiopathic Pulmonary Fibrosis Nosocomial pneumonia : rationalizing the approach to empirical therapy. Managing asthma in expectant mothers. New strategies for the treatment of pulmonary hypertension in sickle cell disease : the rationale for arginine therapy. Antioxidant strategies in respiratory medicine.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1